Drug intelligence / Profile preview

KP8021

Development stage: Preclinical
Lead developer: K Pharma
Modality: Gene Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

KP8021 is a regenerative cell therapy candidate consisting of gene-modified induced pluripotent stem cell (iPSC)-derived neural progenitor cells (NPCs). Developed by K Pharma, Inc., a Keio University spin-off, the therapy is specifically designed for the treatment of chronic spinal cord injury. Unlike acute phase treatments, KP8021 utilizes genetic modification to enhance the survival, differentiation, and integration of the transplanted neural cells within the inhibitory environment of a chronic spinal lesion. The program is currently in the preclinical stage, focusing on optimizing gene introduction techniques to improve functional recovery outcomes.

Beyond the preview

Go deeper on KP8021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP8021.

Explore the full profile